A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
12/2006
12/21/2006	US20060286162 Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
12/21/2006	US20060286161 Injectable liposomal depots for delivering active ingredients
12/21/2006	US20060286160 Nicotine transdermal delivery system
12/21/2006	US20060286159 Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect
12/21/2006	US20060286158 Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
12/21/2006	US20060286154 Absorbant materials with bactericides for sheets or diapers
12/21/2006	US20060286153 Anti-viral lotion tissue and methods for making and using the same
12/21/2006	US20060286152 poly(N-isopropylacrylamide)polyurethane hydrogel; coupling of chitosan to surface of hydrogel can not only improve the handle and skin affinity, but also render facial mask antibacterial; hydrogel layer can load nutrients such as vitamins, aloe extract; can reversibly swell, deswell at body temperature
12/21/2006	US20060286144 Reinforced collagen scaffold
12/21/2006	US20060286142 Gold surfaces coated with a thermostable chemically resistant polypeptide layer and applications thereof
12/21/2006	US20060286141 Systems for gel-based medical implants
12/21/2006	US20060286138 Novel biodegradable aliphatic polyesters and pharmaceutical compositions and applications thereof
12/21/2006	US20060286132 Use of stellate ganglion block for the treatment of sexual dysfunction
12/21/2006	US20060286131 Use of stellate ganglion block for the treatment of hot flashes and other conditions
12/21/2006	US20060286130 Sterile gelling agents
12/21/2006	US20060286087 Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
12/21/2006	US20060286048 Dustless powder materials
12/21/2006	US20060286043 Delivery of antihistamines through an inhalation route
12/21/2006	US20060286042 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone
12/21/2006	US20060286040 Medicament compositions comprising a heterocyclic compound and an anticholinergic
12/21/2006	US20060283465 Smart drug delivery system and a method of implementation thereof
12/21/2006	DE19842744B4 Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl und deren Verwendung Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil and their use
12/21/2006	CA2632375A1 Diclofenac formulations and methods of use
12/21/2006	CA2612288A1 Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
12/21/2006	CA2612175A1 Particles having hydrophobic material therein
12/21/2006	CA2611917A1 Injection
12/21/2006	CA2611883A1 Method for solubilizing metronidazole
12/21/2006	CA2611869A1 Pharmaceutical composition comprising an organopolysiloxane elastomer and a solubilized active principle
12/21/2006	CA2611760A1 Oral dosage form comprising an antimisuse system
12/21/2006	CA2611715A1 Methods and systems for neural maintenance and regeneration
12/21/2006	CA2611523A1 Stable fixed-dose unitary formulations comprising tenofovir, a surfatant and efavirenz
12/21/2006	CA2611475A1 Nanoparticulate ebastine formulations
12/21/2006	CA2611224A1 Method for handling adhesive laminate sections
12/21/2006	CA2611190A1 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
12/21/2006	CA2610767A1 Tanaproget compositions containing ethinyl estradiol
12/21/2006	CA2610422A1 Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
12/21/2006	CA2610412A1 Direct compression formulation of dpp-iv inhibitors and glitazones, and process
12/21/2006	CA2604078A1 Enteric pharmaceutical formulations of choline salt of fenofibric acid
12/21/2006	CA2573657A1 Nano-particle production
12/21/2006	CA2550704A1 Nicotine transdermal delivery system
12/20/2006	EP1734133A2 Heparanase specific molecular probes and their use in research and medical applications
12/20/2006	EP1734037A2 Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol"
12/20/2006	EP1733758A1 Methods for administration of a farnesyl dibenzodiazepinone
12/20/2006	EP1733755A1 An apparatus containing a composition
12/20/2006	EP1733754A1 An apparatus containing a composition
12/20/2006	EP1733753A1 An apparatus containing a composition
12/20/2006	EP1733741A2 O/W-emulsions comprising one or several bioquinones and an elevated amount of glycerine
12/20/2006	EP1733735A2 Methods and products for inducing mucosal immunity
12/20/2006	EP1733734A2 Placental alkaline phosphatase to control diabetes
12/20/2006	EP1733725A1 Farmaceutical formulations comprising at least one HIV protease inhibiting compound
12/20/2006	EP1733720A1 Composition comprising reduced-form coenzyme q10 and carotenoid compound
12/20/2006	EP1733719A1 Percutaneous absorption-type pharmaceutical preparation using a metal chloride, preferably sodium chloride, for preventing cohesive failure
12/20/2006	EP1733718A1 Bio-agent delivery systems based on coated degradable biocompatible hydrogels
12/20/2006	EP1733397A2 Anti-infectious hydrogel compositions
12/20/2006	EP1732953A2 Hydroxyethyl starch
12/20/2006	EP1732676A1 Process for the formation of particulate material
12/20/2006	EP1732606A2 Formulations decreasing infectivity of pulmonary diseases
12/20/2006	EP1732600A2 Uses of anti-ctla-4 antibodies
12/20/2006	EP1732590A2 New pharmaceutical composition based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins
12/20/2006	EP1732576A1 Method for the photostabilisation of phycobiliproteins in an aqueous extract, compositions containing stabilised phycobiliproteins and use of stabilised phycobiliproteins
12/20/2006	EP1732565A1 Sustained-release oral molsidomine composition for treating atherosclerosis
12/20/2006	EP1732555A1 Opioid delivery system
12/20/2006	EP1732535A1 Injectable composition for the treatment of cancers
12/20/2006	EP1732529A1 Gossypol co-crystals and the use thereof
12/20/2006	EP1732528A1 Bazedoxifene acetate solid dispersion formulations
12/20/2006	EP1732526A2 Salmeterol inhalation formulations
12/20/2006	EP1732525A1 Amorolfine patch for treating onychomycosis
12/20/2006	EP1732524A2 Methods and compositions for treatment of ion imbalances
12/20/2006	EP1732523A1 Ion binding polymers and uses thereof
12/20/2006	EP1732522A2 Gastric retention system
12/20/2006	EP1732521A2 Compression-coated tablets and manufacture thereof
12/20/2006	EP1732520A1 Drug delivery system based on polyethylene vinylacetate copolymers
12/20/2006	EP1732519A1 Oral matrix formulations comprising licarbazepine
12/20/2006	EP1732518A1 Clarithromycin extended release formulation
12/20/2006	EP1732517A1 Prolonged-release compositions comprising torasemide and a matrix-forming polymer
12/20/2006	EP1732516A1 Ion binding compositions
12/20/2006	EP1732515A1 Dry powder preparations for pre-metered dpi
12/20/2006	EP1732514A1 Crystalline composition containing escitalopram oxalate
12/20/2006	EP1732513A2 Rosiglitazone formulations
12/20/2006	EP1732512A2 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
12/20/2006	EP1732511A1 Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose
12/20/2006	EP1732503A1 Film products having controlled disintegration properties
12/20/2006	EP1732487A1 Medical plaster for application on the skin
12/20/2006	EP1732486A1 Drug-enhanced adhesion prevention
12/20/2006	EP1732485A2 Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
12/20/2006	EP1635793A4 A composition for an enteric coating of natural product containing lectin
12/20/2006	EP1633324B1 Ophthalmic compositions containing a synergistic combination of three polymers
12/20/2006	EP1561460B1 Nanoparticles for the administration of active ingredients, method of producing said particles and composition containing same
12/20/2006	EP1523335B1 Injectable depot formulation comprising crystals of iloperidone
12/20/2006	EP1519745B1 Method to enhance an immune response of nucleic acid vaccination
12/20/2006	EP1496095B1 Refrigerant compositions and uses thereof
12/20/2006	EP1474152B1 Orodispersible pharmaceutical composition comprising ivabradine
12/20/2006	EP1357903B1 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL) ETHOXY\|PHENOXY)-2-(4-METHOXYPHENYL) BENZO b\|THIOPHENE AND SALTS THEREOF
12/20/2006	EP1343473B1 Pharmaceutical dronedarone composition for parenteral administration
12/20/2006	EP1276472B1 Formulations for use in inhaler devices
12/20/2006	EP1235835B1 Chromium-histidine complexes as nutrient supplements
12/20/2006	EP1121103B1 Orally disintegrable tablets comprising a benzimidazole
12/20/2006	EP1023075B1 Liquid presentations of oxazaphosphorine-containing pharmaceutical products
12/20/2006	EP1020177B1 Multilayered soft capsule for eliminating foul breath and process for producing the same
12/20/2006	EP0943326B2 Powdery composition for nasal administration

1 ... 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 ... 2991